Home > Press > Nanosphere Announces Exercise of Over-Allotment Option and Closing of Initial Public Offering
Abstract:
Nanosphere, Inc. (NASDAQ: NSPH), a nanotechnology-based molecular diagnostics company, today announced that the underwriters of Nanosphere's recent initial public offering of its common stock exercised in full their over-allotment option to purchase an additional 1,050,000 shares of Nanosphere's common stock at $14.00 per share, less underwriting discounts and commissions. The option was granted in connection with Nanosphere's initial public offering of 7,000,000 shares. The closing of the sale of all 8,050,000 shares by Nanosphere to the underwriters occurred earlier today.
Credit Suisse Securities (USA) LLC acted as the sole book-running manager for the offering. Piper Jaffray & Co., Leerink Swann LLC, and Allen & Company LLC acted as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 31, 2007. This offering is being made solely by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained from Credit Suisse, Prospectus Department, One Madison Avenue, Level 1B, New York, NY 10010 (telephone number: (212) 325-2580).
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
####
About Nanosphere, Inc.
Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene® System for direct genomic and ultra-sensitive protein detection. This easy to use and cost effective platform enables simple, low cost and highly sensitive genomic and protein testing on a single platform. Nanosphere is based in Northbrook, IL.
For more information, please click here
Contacts:
Schwartz Communications, Inc.
Laura Kempke or Andrea tenBroek, 781-684-0770
Copyright © Business Wire 2007
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||